These parliamentary studies, though seemingly low-profile, carry significant implications for medicine access. The Canadian government's emphasis on public investment in research and development (R&D) and biomanufacturing, while boosting private enterprise, may inadvertently prioritize profit over public health. The first study, misleadingly titled 'Private Sector Investment in Research and Development in Canada', aims to advance the commercialization of Canadian university research. However, this approach risks handing publicly funded research to private interests, who then control access and pricing, potentially impacting medicine availability. The second study, on 'Canada's Pharmaceutical Sovereignty', highlights the country's struggle with drug shortages and vaccine access during the COVID-19 pandemic. Canada's reliance on private sector companies for biomanufacturing, despite public investment, raises concerns about control and sovereignty. The pandemic prompted increased public investment in domestic biomanufacturing, but the focus on profit-driven companies may hinder effective pharmaceutical sovereignty. The text emphasizes the need for a balanced approach, where public funds and R&D are transferred to the private sector in health-critical areas, ensuring public benefits. Examples include the University of British Columbia's innovations, where publicly funded research led to private company profits, yet Canada still paid for the drug. The reliance on private industry for market entry disadvantages medicines with significant public health impact. The WHO's Essential Medicines, crucial for diseases like tuberculosis, are not sold in Canada due to profitability concerns, creating access challenges. Canadian research breakthroughs face similar issues, as seen with the Ebola vaccine saga. The text concludes by urging the Canadian government to shift focus from subsidizing the pharmaceutical industry to addressing domestic gaps, prioritizing health needs over industry desires, and ensuring effective pharmaceutical sovereignty through proactive measures.
